Global Hyperlipidemia Drugs Market Size study & Forecast, by Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, PCSK9 Inhibitors, Combination, Miscellaneous) and Regional Analysis, 2023-2030

Global Hyperlipidemia Drugs Market Size study & Forecast, by Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, PCSK9 Inhibitors, Combination, Miscellaneous) and Regional Analysis, 2023-2030

Global Hyperlipidemia Drugs Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Hyperlipidemia drugs, also known as lipid-lowering drugs or lipid-lowering agents, are medications used to manage and treat high levels of lipids (fats) in the blood, particularly cholesterol and triglycerides. Hyperlipidemia is a condition characterized by elevated levels of lipids, which can lead to an increased risk of cardiovascular diseases such as heart attacks and strokes. The Hyperlipidemia Drugs market is expanding because of factors such as the rising prevalence of cardiovascular diseases and the rise in the prevalence of hyperlipidemia across the globe.

The rising prevalence of hyperlipidemia, primarily attributed to unhealthy lifestyles, sedentary habits, and poor dietary choices, has driven the demand for lipid-lowering medications. The World Health Organisation (WHO) estimates that hypercholesterolemia causes more than 2.6 million deaths annually. Additionally, Hyperlipidemia, also known as high cholesterol, is a significant risk factor for cardiovascular diseases such as heart disease and stroke. The rising prevalence of cardiovascular disease worldwide has been a driving factor in the growth of Hyperlipidemia Drugs. The American College of Cardiology reports that by 2030, there would be around 29 million Americans with a diagnosis of cardiovascular disease, up from 6.95 million in the year 2021. In 2020, 244.1 million people worldwide were living with ischemic heart disease. Thus, the rising prevalence of cardiovascular diseases is driving the market growth. In addition, increasing clinical trials on drug development and rising healthcare expenditure are creating new opportunities for market growth. However, the availability of different treatments, adverse effects, and safety concerns stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Hyperlipidemia Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of key market players, rising prevalence of cardiovascular disease, advancement in drug development, rising number of clinical trials activities and healthcare expenditure in the region. Whereas, Asia Pacific is projected to grow a significant rate owing to factors such as the rising prevalence of heart diseases, rising healthcare expenditure, rising healthcare expenditure, active participation of government in the region.

Major market player included in this report are:
Amgen Inc.
AstraZeneca PLC
Daiichi Sankyo Company Limited
Eli Lilly and Company
Esperion Therapeutics Inc
GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
Immuron Limited
Ionis Pharmaceuticals Inc.
Merck & Co. Inc.
Sanofi S.A.

Recent Developments in the Market:
In January 2023, AstraZeneca entered signed an agreement to acquire CinCor Pharma, Inc., a clinical-stage biopharmaceutical business based in the US that specializes in developing innovative medications for chronic kidney disease and safe, uncontrolled hypertension.
In May 2022, Zydus Lifesciences launched its bempedoic acid drug under the trade name Bemdac in India to treat high levels of harmful cholesterol.

Global Hyperlipidemia Drugs Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Drug Class, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug Class:
Statins
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
Fibric Acid Derivatives
PCSK9 Inhibitors
Combination
Miscellaneous

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Amgen Inc.
AstraZeneca PLC
Daiichi Sankyo Company Limited
Eli Lilly and Company
Esperion Therapeutics Inc
GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
Immuron Limited
Ionis Pharmaceuticals Inc.
Merck & Co. Inc.
Sanofi S.A.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.